Korean J Intern Med.
2017 Jul;32(4):622-630. 10.3904/kjim.2016.219.
Treatment of diabetic kidney disease: current and future targets
- Affiliations
-
- 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea. mdkmk@dsmc.or.kr
- KMID: 2387706
- DOI: http://doi.org/10.3904/kjim.2016.219
Abstract
- Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease in Korea and worldwide, and is a risk factor for the development of cardiovascular complications. The conventional treatments for DKD are control of blood glucose and blood pressure levels by inhibiting the renin-angiotensin system. However, the prevalence of DKD continues to increase and additional therapies are required to prevent or ameliorate the condition. Many drugs have been, or are being, developed to target the molecular mechanisms in play in DKD. This review focuses on DVD treatment, considering current and emerging therapeutic targets and the clinical trial-based evidence.
